EAVI2020 quarterly newsletter | April 2021
In this issue:
- EAVI2020 receives extension and clinical trials resume
- EAVI2020 consortium at HIVR4P
- Students in Focus: Narcís Saubi, Vall d’Hebron Research Institute (VHIR)
- Publications with EAVI2020
- EAVI2020 out and about: International Women’s Day
- HIV/AIDS news: COVID-19 disruptions to HIV prevention could increase new infections amongst men
- Other news: EAVI2020 lead investigator, Prof Robin Shattock profiled in The Lancet
Foreword from Robin
Following a challenging year in the face of the COVID-19 pandemic the consortium is excited to be progressing again at full speed.
We were delighted to receive a no cost extension from the EU that will allow us to complete our full programme of research and make up for delays caused by multiple lockdowns across the EU. We continue to invest in the training and mentorship of gifted young researchers to ensure a rich talent pool for the future, some of whom are highlighted in this newsletter. In our final year we are conducting seven clinical trials to evaluate ten new vaccine candidates, demonstrating an unprecedented level of translation from discovery to clinical evaluation. Our clinical trials are underpinned by an integrated approach designed to maximise our understanding of human immunity to vaccination and the pathways for driving B and T cell breadth to combat the extraordinary diversity of circulating HIV strains. These studies will be the culmination of our discovery program, will significantly expand scientific understanding and provide a pipeline of products with potential for moving into later stage product development. The entire EAVI2020 team are galvanised around maximising the potential of our discovery program and building a sustainable legacy for HIV vaccine research in the EU.
Professor Robin Shattock
EAVI2020 coordinator and on behalf of the EAVI2020 consortium